Previously, we reported that embryonic carcinoma (EC) cells express high levels of stemness-related transcription factors, and that targeting one of the factors, Nanog, using a histone deacetylase inhibitor can serve as an improved therapeutic strategy for poorly differentiated cancer stem-like cells, involving the suppression of EC proliferation and tumorigenesis [21]. This evidence concerns the gene NANOG and cancer.